Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2025 16:08 ET | Source: Abivax

Abivax Presents Third Quarter 2025 Financial Results

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m....
December 15, 2025 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference...
December 15, 2025 10:30 ET | Source: The Lundquist Institute for Biomedical Innovation

The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID

Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal...
December 15, 2025 10:08 ET | Source: Animal Alliance of Canada

Experts Warn: “Dogs and Cats Will Not Be Safe From Invasive Research Until Ontario Closes Every Loophole”

Ontario takes historic steps to end invasive research on dogs and cats, but experts warn loopholes remain and stronger protections are needed.
December 14, 2025 08:01 ET | Source: Vaxxas Pty Ltd

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration...
December 14, 2025 04:49 ET | Source: InnoCare Pharma

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.
December 12, 2025 17:00 ET | Source: BioTech Breakthrough

BioLizard Wins 2025 BioTech Breakthrough Award For “BioInformatics Innovation of the Year”

LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, an independent market intelligence organization that identifies and honors the top companies, technologies and products shaping...
December 11, 2025 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
December 11, 2025 10:00 ET | Source: Eclipse Energy, Inc.

Eclipse Energy Announces Collaborative Partnership with Weatherford Accelerating Commercialization of Subsurface Clean Energy Technologies

Eclipse Energy today announced a collaborative partnership and capital investment with Weatherford International plc to commercialize subsurface cleantech.
December 11, 2025 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

Matisse Pharmaceuticals receives INN (International Non-proprietary Name) isupartob sodium from the WHO recognizing first-in-class drug status for M6229.